Literature DB >> 10643815

Human amyloid-beta1-42 applied in vivo inhibits the fast axonal transport of proteins in the sciatic nerve of rat.

P Kasa1, H Papp, I Kovacs, M Forgon, B Penke, H Yamaguchi.   

Abstract

Human amyloid-beta1-42 has been suggested to be a pathogenetic factor in Alzheimer's disease. The precise mechanism by which this peptide causes the degeneration of neurons in the affected brain is not yet fully understood. By using immunohistochemistry we explored the inhibitory effects of human amyloid-beta1-42 applied in vivo on the fast axonal transport of acetylcholinesterase, the amyloid precursor protein, the vesicular acetylcholine transporter and synaptophysin in the sciatic nerve of rat. Our findings provide evidence for the in vivo neurotoxic effect of human amyloid-beta peptide.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10643815     DOI: 10.1016/s0304-3940(99)00863-0

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  11 in total

Review 1.  Axonal degeneration in Alzheimer's disease: when signaling abnormalities meet the axonal transport system.

Authors:  Nicholas M Kanaan; Gustavo F Pigino; Scott T Brady; Orly Lazarov; Lester I Binder; Gerardo A Morfini
Journal:  Exp Neurol       Date:  2012-06-19       Impact factor: 5.330

2.  C-terminal fragments of amyloid-beta peptide cause cholinergic axonal degeneration by a toxic effect rather than by physical injury in the nondemented human brain.

Authors:  Peter Kasa; Henrietta Papp; Janos Zombori; Peter Mayer; Frederic Checler
Journal:  Neurochem Res       Date:  2003-04       Impact factor: 3.996

Review 3.  Kinesin molecular motors: transport pathways, receptors, and human disease.

Authors:  L S Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

Review 4.  Aβ Influences Cytoskeletal Signaling Cascades with Consequences to Alzheimer's Disease.

Authors:  Ana Gabriela Henriques; Joana Machado Oliveira; Liliana Patrícia Carvalho; Odete A B da Cruz E Silva
Journal:  Mol Neurobiol       Date:  2014-10-26       Impact factor: 5.590

Review 5.  Axonal transport and neurodegenerative disease: can we see the elephant?

Authors:  Lawrence S B Goldstein
Journal:  Prog Neurobiol       Date:  2012-04-01       Impact factor: 11.685

6.  Similar pattern of peripheral neuropathy in mouse models of type 1 diabetes and Alzheimer's disease.

Authors:  C G Jolivalt; N A Calcutt; E Masliah
Journal:  Neuroscience       Date:  2011-12-09       Impact factor: 3.590

7.  Differential roles of Aβ processing in hypoxia-induced axonal damage.

Authors:  Melissa G Christianson; Donald C Lo
Journal:  Neurobiol Dis       Date:  2015-03-11       Impact factor: 5.996

8.  Enhanced β-secretase processing alters APP axonal transport and leads to axonal defects.

Authors:  Elizabeth M Rodrigues; April M Weissmiller; Lawrence S B Goldstein
Journal:  Hum Mol Genet       Date:  2012-07-27       Impact factor: 6.150

9.  Is abnormal axonal transport a cause, a contributing factor or a consequence of the neuronal pathology in Alzheimer's disease?

Authors:  Virgil Muresan; Zoia Muresan
Journal:  Future Neurol       Date:  2009-11-01

10.  Glycogen synthase kinase-3 inhibition prevents learning deficits in diabetic mice.

Authors:  Matthew R King; Nicholas J Anderson; Lucie S Guernsey; Corinne G Jolivalt
Journal:  J Neurosci Res       Date:  2013-01-30       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.